MPM Raises $400m To Build Early-Stage Biotechs
The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.
You may also be interested in...
Astellas has exercised an option to acquire Potenza, paying up to $404.7m in cash for the private US venture in a deal that will boost its presence in immuno-oncology.
It has taken almost two decades but it looks as though Erytech could get approval for eryaspase in the US in two indications next year – acute lymphoblastic leukemia and pancreatic cancer.
The company's pharma chief Marie-France Tschudin does not expect Entresto's "unique position" in heart failure to be threatened by SGLT2 inhibitors such as Jardiance and Farxiga, saying those drugs are add-ons that will be used predominantly in diabetes patients.